HAPILA brings advanced API and synthesis capabilities to Chemspec Europe 2024

Gera, Germany: – High-potency active ingredient specialist CDMO HAPILA GmbH (HAPILA) will return for the seventh successive time to the influential Chemspec Europe trade show, this time in Düsseldorf, Germany.

HAPILA has been a consistent presence at Chemspec since 2016 and will again be a prominent exhibitor at the show from Booth J50 in Hall 3 of the Messe Düsseldorf, with a display showcasing its extensive range of CDMO services, including advanced synthesis and API development.

The stand will also represent the work of HAPILA’s strategic marketing and sales partner Transo-Pharm Handels-GmbH, based in Siek near Hamburg, Germany.

Drinks Invitation

HAPILA will be serving soft drinks from its stand and invites visitors to take some refreshment while talking about their needs in synthesis and development of active ingredients.

The HAPILA team in Düsseldorf will be led by CEO Dr. Uwe Müller and will also include Head of Quality Control Kristin Kirmße and Project Manager Development Dr. Thomas Rosin. They will emphasize HAPILA’s distinctive identity as both a CDMO as well as CEP-holder of its own API.

New APIs under development

“Therefore, we are able to promote our services in Synthesis development, scale up of existing synthesis, particle design and the development of difficult purification of small molecules and speak with interested companies about our own APIs – both existing and future ones now under development,” said Dr. Müller.

“Of course, we will also take advantage of this show’s extensive reach and prominent place within our industry to meet our long-standing business partners in person, discuss our future strategies, or simply to refresh personal contacts,” he added.

About HAPILA GmbH

HAPILA GmbH is a contract developing and manufacturing organization (CDMO) that provides high-value services to pharma, biotech and fine chemicals client companies in the development and cGMP manufacture of active pharmaceutical ingredients (APIs).

HAPILA is an independent company with particular experience in GMP-related development and GMP manufacturing, offering full regulated service for API (IMPD, ASMF) to very high scientific and quality assurance (QA) levels.

It supports the development and manufacture of drug products with patented processes and in-depth experience in the API value-creation chain from synthesis through purification to particle design.

The company’s mission is to supply exclusive products of highest quality, potency and safety in compliance with GMP and environmental protection guidelines. All HAPILA teamwork is focused on product quality and customer satisfaction.

All HAPILA chemical synthesis is carried out in-house at its GMP certified laboratories at Gera, Thuringia, in east-central Germany.

When combined with purification and particle design, HAPILA’s chemical synthesis services cover the complete API value-creation chain, enabling it to be a highly efficient bridge-builder between API production and pharmaceutical end-use.

For more information, visit: www.hapila.de/ecom

About Chemspec Europe 2024

The International Exhibition for Fine and Specialty Chemicals, Chemspec Europe, is the continent’s premier sourcing and networking event for manufacturers, suppliers and distributors of fine and specialty chemicals. Chemspec Europe is renowned for its specialized profile, presenting visitors and exhibitors with a platform to share knowledge about products and solutions.

The 37th Chemspec Europe expo (Chemspec 2024) will again be a two-day event opening June 19th in Hall 3 of the Messe Exhibition Center in Düsseldorf, Germany. The show is projected to surpass the 2023 show in Frankfurt that attract more than 4,100 industry professionals from all over the world and featured some 350 exhibitors from 62 countries worldwide.

The event is organized by Mack-Brooks Exhibitions with further information at https://www.chemspeceurope.com

Resources

Click on HAPILA at Chemspec 2024 to see exhibitor profile.
Click on HAPILA Track Record for further information.
Follow HAPILA on LinkedIn.